It was shown that the proliferation of imatinib-sensitive and imatinib-resistant CML cells inhibited by JOA via inducing cell differentiation evidenced by the morphological alteration and the increase of the expression of CD11b, CD13, CD14, CD15 or F4/80 in BaF3-T315I, BaF3-WT and K562 cells. The gene discussed is ITGAM; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.